HSBC Holdings’s Ovid Therapeutics OVID Stock Holding History

HSBC Holdings’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-19,220	Closed	-$6.01K	–	3029
2025 Q2	$6.01K	Buy	+19,220	New	+$5.79K	﹤0.01%	3001

Other funds holding OVID

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

HSBC Holdings's OVID Position: Q3 2025 in Review

HSBC Holdings sold out of Ovid Therapeutics (OVID) in Q3 2025, closing a stake of 19,220 shares — an estimated $6.01K sold.

HSBC Holdings first reported a position in OVID in Q2 2025 and held it in 1 quarter. The position peaked at $6.01K in Q2 2025. 81 funds tracked by Wall St. Rank hold OVID as of Q3 2025.

HSBC Holdings reported no remaining Ovid Therapeutics position as of Q3 2025 after selling out during the quarter.
HSBC Holdings sold 19,220 Ovid Therapeutics shares in Q3 2025, an estimated $6.01K.
HSBC Holdings first reported a position in Ovid Therapeutics in Q2 2025 and held it in 1 quarter.
HSBC Holdings's Ovid Therapeutics position peaked at $6.01K in Q2 2025.
81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2025.

Based on HSBC Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.